Helix BioPharma (TSE:HBP) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Helix BioPharma has amended its acquisition agreements with Laevoroc Immunology and Laevoroc Chemotherapy to set fixed numbers of common shares issuable, ensuring flexibility for potential financing deals and protecting shareholder value. The adjustments come ahead of a potential financing opportunity that could affect share dilution and valuation. The transactions will require shareholder approval and adherence to stock exchange conditions.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.